Inventiva Plans To Launch $125M American Depositary Shares Offering

Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced that it plans to offer and sell approximatively $125 million (representing approximately €108 million) of new American Depositary Shares ("ADSs") each representing one new ordinary share of the Company with a nominal value of €0.01, in an underwritten public offering in the United States only (the "Offering"). The Company's ADSs are listed on the Nasdaq Global Market under the ticker symbol "IVA" and the Company's ordinary shares are listed on the regulated market of Euronext in Paris ("Euronext") under the symbol "IVA". All securities to be sold in the Offering will be offered solely by the Company.

The Company intends to use the net proceeds from the Offering, together with existing cash and cash equivalents, mainly to fund the continuation of the Company's NATiV3 Phase 3 clinical trial as well as the continuation of the preparation and initiation of the outcome trial and for commercialization activities, working capital and general corporate purposes.